Biodexa Pharmaceuticals (BDRX) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Biodexa Pharmaceuticals has submitted its Form 6-K to the SEC to meet its reporting requirements for the fiscal year ending December 31, 2024, with agreement on statements from their former auditors, Forvis Mazars LLP. This filing reflects the company’s ongoing compliance with international financial reporting standards, a key concern for investors tracking Biodexa’s financial health.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
